A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms GRID
  • Sponsors Bayer
  • Most Recent Events

    • 12 Sep 2017 Results of exploratory analysis assessing relationship between tumor growth rate and progression-free survival and overall survival for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib, were presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Sep 2017 According to a Bayer media release, data regarding tumor growth rate analysis will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
    • 02 Jun 2017 Results of a exploratory analysis from GRID and DECISION trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top